Oncoinvent ASA (CHIX:ONCINO) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr11,961.53
! 5 Warning Signs
View Full Analysis

What is Oncoinvent ASA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Oncoinvent ASA Quality Rank Related Terms

CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 91.3% below its estimated GF Value™ of kr11,961.53.

Key valuation signals for CHIX:ONCINO:

  • Quality Rank:
  • GF Value™: kr11,961.53 vs. price of kr1,039.91 (91.3% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr11,961.53
GF Value